|
|
 Previous Article | Table of Contents | Next Article 
Incidence of TEL/AML1 Fusion Gene Analyzed Consecutively in Children With Acute Lymphoblastic Leukemia in Relapse
J. Harbott,
S. Viehmann,
A. Borkhardt,
G. Henze, and
F. Lampert
From the Department of General Pediatrics, Hematology and Oncology, Children's University Hospital, Giessen, Germany, and Children's University Hospital, Rudolf-Virchow-Klinikum, Humboldt University, Berlin, Germany.
The translocation t(12; 21)(p13; q22) is difficult to detect by classic cytogenetics. However, using fluorescence in situ hybridization (FISH) and by screening for the TEL/AML1 rearrangement by the polymerase chain reaction (PCR), it has been demonstrated to be the most frequent known structural chromosomal abnormality in childhood acute lymphoblastic leukemia (ALL). It is closely correlated with a B-cell precursor (BCP) phenotype and is considered a favorable prognostic factor. However, little is known about the incidence of the translocation in relapsed patients and the duration of complete remission (CR) in children expressing the TEL/AML1 fusion gene. We therefore examined 49 bone marrow samples from children with ALL at first or second relapse that were consecutively mailed to our laboratory to test for the presence of t(12; 21) using reverse transcriptase (RT)-PCR. The TEL/AML1 rearrangement could be identified in nine of 44 (20%) of the patients, a result similar to the reported incidence at diagnosis. Most of the TEL/AML1-positive children showed no adverse clinical features at diagnosis (eg, white blood cell [WBC] count <100 × 109/L or age <10 years), and regarding these data, there were no differences versus children who were negative for the fusion gene. However, the period of remission was about 1 year longer in children expressing TEL/AML1 (P = .046), and the majority of relapses in this group appeared late (<2 years after diagnosis). Our findings therefore reinforce the urgent need for further prospective studies with a long follow-up period to determine the true prognostic significance of t(12; 21) and to avoid premature changes of treatment strategies.
Blood, Vol. 90 No. 12 (December 15), 1997:
pp. 4933-4937
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. E. Rubnitz, D. Wichlan, M. Devidas, J. Shuster, S. B. Linda, J. Kurtzberg, B. Bell, S. P. Hunger, A. Chauvenet, C.-H. Pui, et al.
Prospective Analysis of TEL Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
J. Clin. Oncol.,
May 1, 2008;
26(13):
2186 - 2191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Roman-Gomez, A. Jimenez-Velasco, X. Agirre, J. A. Castillejo, G. Navarro, M. J. Calasanz, L. Garate, E. San Jose-Eneriz, L. Cordeu, F. Prosper, et al.
CpG Island Methylator Phenotype Redefines the Prognostic Effect of t(12;21) in Childhood Acute Lymphoblastic Leukemia.
Clin. Cancer Res.,
August 15, 2006;
12(16):
4845 - 4850.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Loh, M. A. Goldwasser, L. B. Silverman, W.-M. Poon, S. Vattikuti, A. Cardoso, D. S. Neuberg, K. M. Shannon, S. E. Sallan, and D. G. Gilliland
Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01
Blood,
June 1, 2006;
107(11):
4508 - 4513.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Pui, D. Pei, J. T. Sandlund, D. Campana, R. C. Ribeiro, B. I. Razzouk, J. E. Rubnitz, S. C. Howard, N. Hijiya, S. Jeha, et al.
Risk of Adverse Events After Completion of Therapy for Childhood Acute Lymphoblastic Leukemia
J. Clin. Oncol.,
November 1, 2005;
23(31):
7936 - 7941.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Growney, H. Shigematsu, Z. Li, B. H. Lee, J. Adelsperger, R. Rowan, D. P. Curley, J. L. Kutok, K. Akashi, I. R. Williams, et al.
Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype
Blood,
July 15, 2005;
106(2):
494 - 504.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B.-M. Frost, E. Forestier, G. Gustafsson, P. Nygren, M. Hellebostad, O. G. Jonsson, J. Kanerva, K. Schmiegelow, R. Larsson, G. Lonnerholm, et al.
Translocation t(12;21) is related to in vitro cellular drug sensitivity to doxorubicin and etoposide in childhood acute lymphoblastic leukemia
Blood,
October 15, 2004;
104(8):
2452 - 2457.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Zaza, W. Yang, L. Kager, M. Cheok, J. Downing, C.-H. Pui, C. Cheng, M. V. Relling, and W. E. Evans
Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis
Blood,
September 1, 2004;
104(5):
1435 - 1441.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Konrad, M. Metzler, S. Panzer, I. Ostreicher, M. Peham, R. Repp, O. A. Haas, H. Gadner, and E. R. Panzer-Grumayer
Late relapses evolve from slow-responding subclones in t(12;21)-positive acute lymphoblastic leukemia: evidence for the persistence of a preleukemic clone
Blood,
May 1, 2003;
101(9):
3635 - 3640.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. A. G. Stams, M. L. den Boer, H. B. Beverloo, J. P. P. Meijerink, R. L. Stigter, E. R. van Wering, G. E. Janka-Schaub, R. Slater, and R. Pieters
Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL
Blood,
April 1, 2003;
101(7):
2743 - 2747.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Moos, E. A. Raetz, M. A. Carlson, A. Szabo, F. E. Smith, C. Willman, Q. Wei, S. P. Hunger, and W. L. Carroll
Identification of Gene Expression Profiles That Segregate Patients with Childhood Leukemia
Clin. Cancer Res.,
October 1, 2002;
8(10):
3118 - 3130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. J. Weston, C. M. McConville, J. R. Mann, P. J. Darbyshire, S. Lawson, J. Gordon, P. A. H. Moss, A. Malcolm, R. Taylor, and T. Stankovic
Molecular Analysis of Single Colonies Reveals a Diverse Origin of Initial Clonal Proliferation in B-Precursor Acute Lymphoblastic Leukemia that Can Precede the t(12;21) Translocation
Cancer Res.,
December 1, 2001;
61(23):
8547 - 8553.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Ford, K. Fasching, E. R. Panzer-Grumayer, M. Koenig, O. A. Haas, and M. F. Greaves
Origins of "late" relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes
Blood,
August 1, 2001;
98(3):
558 - 564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Seeger, A. V. Stackelberg, T. Taube, D. Buchwald, G. Korner, M. Suttorp, W. Dorffel, W. Tausch, and G. Henze
Relapse of TEL-AML1-Positive Acute Lymphoblastic Leukemia in Childhood: A Matched-Pair Analysis
J. Clin. Oncol.,
July 1, 2001;
19(13):
3188 - 3193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Seeger, K.-A. Kreuzer, U. Lass, T. Taube, D. Buchwald, C. Eckert, G. Körner, C.-A Schmidt, and G. Henze
Molecular Quantification of Response to Therapy and Remission Status in TEL-AML1-Positive Childhood ALL by Real-Time Reverse Transcription Polymerase Chain Reaction
Cancer Res.,
March 1, 2001;
61(6):
2517 - 2522.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
N. L. R.-v. Woerden, R. Pieters, A. H. Loonen, I. Hubeek, E. van Drunen, H. B. Beverloo, R. M. Slater, J. Harbott, J. Seyfarth, E. R. van Wering, et al.
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia
Blood,
August 1, 2000;
96(3):
1094 - 1099.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Seeger, D. Buchwald, A. Peter, T. Taube, A. von Stackelberg, G. Schmitt, G. Henze;, M. L. Loh, L. B. Silverman, D. Neuberg, et al.
TEL-AML1 Fusion in Relapsed Childhood Acute Lymphoblastic Leukemia
Blood,
July 1, 1999;
94(1):
374 - 376.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Loh, L. B. Silverman, M. L. Young, D. Neuberg, T. R. Golub, S. E. Sallan, and D. G. Gilliland
Incidence of TEL/AML1 Fusion in Children With Relapsed Acute Lymphoblastic Leukemia
Blood,
December 15, 1998;
92(12):
4792 - 4797.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
